Author Affiliation: Yale University School of Medicine, New Haven, Connecticut (email@example.com).
To the Editor: In the study by Dr Kostis and colleagues,1 the main outcome measures were cardiovascular death and all-cause mortality. After 22 years, approximately 60% of participants from the Systolic Hypertension in the Elderly Program (SHEP) trial died, and less than 50% of the deaths were from a cardiovascular cause. There were no statistically significant differences in all-cause mortality by the various techniques the investigators used in analyzing these data (area between active and placebo survival curves, log-rank test, time to 70th percentile survival). Instead, there were statistically significant differences between the intervention and control groups only for the outcome of cardiovascular death.
Coca S. Life Expectancy After Treatment for Systolic Hypertension. JAMA. 2012;307(13):1368-1369. doi:10.1001/jama.2012.389